The immune checkpoint pathway consisting of the cell membrane-bound molecule
programmed death protein 1 (PD-1) and its ligand PD-L1 has been found to mediate …

Background Immune checkpoint inhibitors have revolutionized cancer therapeutic paradigm
and substantially improved the survival of patients with advanced malignancies. However, a …

Simple Summary The interaction of programmed cell death ligand-1 (PDL1) with its receptor
PD1 inhibits T-cell responses. Blockade of this interaction with monoclonal antibodies leads …

Currently, immunotherapy targeting programmed cell death 1 (PD-1) or programmed death
ligand 1 (PD-L1) has revolutionized the treatment strategy of human cancer patients …

The analysis of secreted protein biomarkers can be a useful non-invasive method of
predicting or monitoring cancer therapeutic response. The increased level of soluble …

Lung cancer remains the first cause of cancer-related death despite many therapeutic
innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily …

Immunotherapy profoundly changed oncology treatment, becoming one of the main
therapeutical strategies. Remarkable improvement has been achieved in survival outcomes …

Lung cancer is the leading cause of death from cancer in Taiwan and throughout the world.
Immunotherapy has revealed promising and significant efficacy in NSCLC, through immune …

Currently, therapeutic methods for advanced and recurrent cervical cancer patients are
limited and unsatisfactory. Immunotherapy is a promising approach for cancer treatment …

Recently, the V-domain immunoglobulin suppressor of T-cell activation (VISTA) was
identified as a negative immune checkpoint regulator (NCR) that is mainly expressed in …